%0 Journal Article
%A Perez, Marco
%A Peinado-Serrano, Javier
%A Garcia-Heredia, Jose Manuel
%A Felipe-Abrio, Irene
%A Tous, Cristina
%A Ferrer, Irene
%A Martin-Broto, Javier
%A Saez, Carmen
%A Carnero, Amancio
%T Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).
%D 2016
%U http://hdl.handle.net/10668/10392
%X Sarcomas are malignant tumors accounting for a high percentage of cancer morbidity and mortality in children and young adults. Surgery and radiation therapy are the accepted treatments for most sarcomas; however, patients with metastatic disease are treated with systemic chemotherapy. Many tumors display marginal levels of chemoresponsiveness, and new treatment approaches are needed. MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. The levels of MAP17 could be used as a prognostic marker to predict the response to bortezomib in hematological malignancies and in breast tumors. Therefore, we analyzed the expression of this oncogene in sarcomas and its relationship with clinico-pathological features, as well as tested whether it can be used as a new biomarker to predict the therapeutic response to bortezomib and new therapies for sarcomas. We found that the levels of MAP17 were related to clinical features and poor survival in a cohort of 69 patients with different sarcoma types, not being restricted to any special subtype of tumor. MAP17 expression is associated with poor overall survival (p
%K MAP17
%K biomarker
%K bortezomib
%K sarcomas
%K PDX
%~